Cyclooxygenase enzyme expression and E series prostaglandin receptor signalling are enhanced in heavy menstruation

Human Reproduction

Volumn 22, Issue 5, 2007, Pages 1450-1456

  Smith, O P Milling ^a   Jabbour, H N ^b   Critchley, H O D ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Cyclooxygenase; Heavy menstruation; Menorrhagia; Prostaglandin receptors

Indexed keywords

CYCLIC AMP; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; MESSENGER RNA; PHOSPHODIESTERASE IV; PROSTAGLANDIN E2; PROSTAGLANDIN RECEPTOR; PROSTAGLANDIN SYNTHASE; 3',5' CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; PROSTAGLANDIN E RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLEEDING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TARGETING; ENDOMETRIUM; ENDOMETRIUM BIOPSY; EXPERIMENTATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MENSTRUAL CYCLE; MENSTRUATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TISSUE CULTURE; BIOSYNTHESIS; ENZYMOLOGY; FOLLICULAR PHASE; LUTEAL PHASE; MENORRHAGIA; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ADULT; CYCLIC AMP; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; FEMALE; FOLLICULAR PHASE; HUMANS; LUTEAL PHASE; MENORRHAGIA; MIDDLE AGED; RECEPTORS, PROSTAGLANDIN E; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 34447096610     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/del503     Document Type: Article

References (39)

1. Adelantado JM, Rees MC, Lopez Bernal A and Turnbull AC (1988) Increased uterine prostaglandin E receptors in menorrhagic women. Br J Obstet Gynaecol 95(2),162-165.
2. Ashby B (1998) Co-expression of prostaglandin receptors with opposite effects: A model for homeostatic control of autocrine and paracrine signaling. Biochem Pharmacol 55(3),239-246.
3. Baird DT, Cameron ST, Critchley HO, Drudy TA, Howe A, Jones RL, Lea RG and Kelly RW (1996) Prostaglandins and menstruation. Eur J Obstet Gynecol Reprod Biol 70(1),15-17.
4. Bartsch O, Bartlick B and Ivell R (2001) Relaxin signalling links tyrosine phosphorylation to phosphodiesterase and adenylyl cyclase activity. Mol Hum Reprod 7(9),799-809.
5. Bartsch O, Bartlick B and Ivell R (2004) Phosphodiesterase 4 inhibition synergizes with relaxin signaling to promote decidualization of human endometrial stromal cells. J Clin Endocrinol Metab 89(1),324-334.
6. Bonnar J and Sheppard BL (1996) Treatment of menorrhagia during menstruation: Randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. BMJ 313(7057),579-582.
7. Cameron IT, Haining R, Lumsden MA, Thomas VR and Smith SK (1990) The effects of mefenamic acid and norethisterone on measured menstrual blood loss. Obstet Gynecol 76(1),85-88.
8. Coleman RA, Smith WL and Narumiya S (1994) International Union of Pharmacology classification of prostanoid receptors: Properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 46(2),205-229.
9. Coulter A, Kelland J, Peto V and Rees MC (1995) Treating menorrhagia in primary care. An overview of drug trials and a survey of prescribing practice. Int J Technol Assess Health Care 11(3),456-471.
10. Critchley HO, Abberton KM, Taylor NH, Healy DL and Rogers PA (1994) Endometrial sex steroid receptor expression in women with menorrhagia. Br J Obstet Gynaecol 101(5),428-434.
11. Critchley HO, Robertson KA, Forster T, Henderson TA, Williams AR and Ghazal P (2006) Gene expression profiling of mid to late secretory phase endometrial biopsies from women with menstrual complaint. Am J Obstet Gynecol 195(2),406e1-406e16.
12. van Eijkeren MA, Scholten PC, Christiaens GC, Alsbach GP and Haspels AA (1986) The alkaline hematin method for measuring menstrual blood loss - a modification and its clinical use in menorrhagia. Eur J Obstet Gynecol Reprod Biol 22(5-6),345-351.
13. Eldred JM and Thomas EJ (1994) Pituitary and ovarian hormone levels in unexplained menorrhagia. Obstet Gynecol 84(5),775-778.
14. Grosser T, Fries S and FitzGerald GA (2006) Biological basis for the cardiovascular consequences of COX-2 inhibition: Therapeutic challenges and opportunities. J Clin Invest 116(1),4-15.
15. Hallberg N (1964) Determination of menstrual blood loss. Scand J Clin Lab Invest 16,244-248.
16. Hallberg L, Hogdahl AM, Nilsson L and Rybo G (1966) Menstrual blood loss - a population study. Variation at different ages and attempts to define normality. Acta Obstet Gynecol Scand 45(3),320-351.
17. Kooy J, Taylor NH, Healy DL and Rogers PA (1996) Endothelial cell proliferation in the endometrium of women with menorrhagia and in women following endometrial ablation. Hum Reprod 11(5),1067-1072.
18. Lumsden MA, Kelly RW, Abel MH and Baird DT (1986) The concentrations of prostaglandins in endometrium during the menstrual cycle in women with measured menstrual blood loss. Prostaglandins Leukot Med 23(2-3),217-227.
19. Lumsden MA, Kelly RW and Baird DT (1983) Primary dysmenorrhoea: The importance of both prostaglandins E2 and F2 alpha. Br J Obstet Gynaecol 90(12),1135-1140.
20. Milling Smith OP, Battersby S, Sales KJ, Critchley HO and Jabbour HN (2006) Prostacyclin receptor up-regulates the expression of angiogenic genes in human endometrium via cross talk with epidermal growth factor receptor and the extracellular signaling receptor kinase 1/2 pathway. Endocrinology 147(4),1697-1705.
21. Milne SA, Perchick GB, Boddy SC and Jabbour HN (2001) Expression, localization, and signaling of PGE(2) and EP2/EP4 receptors in human nonpregnant endometrium across the menstrual cycle. J Clin Endocrinol Metab 86(9),4453-4459.
22. Noyes RW, Hertig AT. and Rock J (1950) Dating the endometrial biopsy. Fertil Steril 1,3-25.
23. Pickles VR (1957) A plain-muscle stimulant in the menstruum. Nature 180(4596),1198-1199.
24. Prentice A (1999) Fortnightly review. Medical management of menorrhagia. BMJ 319(7221),1343-1345.
25. Prentice A (2000) Health burden of menstrual disorders. In O'Brien S and MacLean A (eds) Disorders of the menstrual cycle. RCOG Press, London, pp. 171-186.
26. Rees MC, Canete-Soler R, Lopez Bernal A and Turnbull AC (1988) Effect of fenamates on prostaglandin E receptor binding. Lancet 2(8610),541-542.
27. Rees MC, Dunnill MS, Anderson AB and Turnbull AC (1984) Quantitative uterine histology during the menstrual cycle in relation to measured menstrual blood loss. Br J Obstet Gynaecol 91(7),662-666.
28. Regan JW (2003) EP2 and EP4 prostanoid receptor signaling. Life Sci 74(2-3),143-153.
29. Reid PC and Mukri F (2005) Trends in number of hysterectomies performed in England for menorrhagia: Examination of health episode statistics, 1989 to 2002-3. BMJ 330(7497),938-939.
30. Sales KJ and Jabbour HN (2003) Cyclooxygenase enzymes and prostaglandins in pathology of the endometrium. Reproduction 126(5),559-567.
31. Sales KJ, Maudsley S and Jabbour HN (2004) Elevated prostaglandin EP2 receptor in endometrial adenocarcinoma cells promotes vascular endothelial growth factor expression via cyclic 3′,5′-adenosine monophosphate-mediated transactivation of the epidermal growth factor receptor and extracellular signal-regulated kinase 1/2 signaling pathways. Mol Endocrinol 18(6),1533-1545.
32. Sanz MJ, Cortijo J and Morcillo EJ (2005) PDE4 inhibitors as new anti-inflammatory drugs: Effects on cell trafficking and cell adhesion molecules expression. Pharmacol Ther 106(3),269-297.
33. Smith SK, Abel MH, Kelly RW and Baird DT (1981) Prostaglandin synthesis in the endometrium of women with ovular dysfunctional uterine bleeding. Br J Obstet Gynaecol 88(4),434-442.
34. Sonoshita M, Takaku K, Sasaki N, Sugimoto Y, Ushikubi F, Narumiya S, Oshima M and Taketo MM (2001) Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(delta 716) knockout mice. Nat Med 7(9),1048-1051.
35. Talbi S, Hamilton AE, Vo KC, Tulac S, Overgaard MT, Dosiou C, Le Shay N, Nezhat CN, Kempson R, Lessey BA et al. (2006) Molecular phenotyping of human endometrium distinguishes menstrual cycle phases and underlying biological processes in normo-ovulatory women. Endocrinology 147(3),1097-1121.
36. Ullrich V, Zou MH and Bachschmid M (2001) New physiological and pathophysiological aspects on the thromboxane A(2)-prostacyclin regulatory system. Biochim Biophys Acta 1532(1-2),1-14.
37. Vane JR, Bakhle YS and Botting RM (1998) Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 38,97-120.
38. Weeks AD, Duffy SR and Walker JJ (2000) A double-blind randomised trial of leuprorelin acetate prior to hysterectomy for dysfunctional uterine bleeding. Br J Obstet Gynaecol 107(3),323-328.
39. Willman EA, Collins WP and Clayton SG (1976) Studies in the involvement of prostaglandins in uterine symptomatology and pathology. Br J Obstet Gynaecol 83(5),337-341.